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Summary
Subclinical hypothyroidism, which is defined as elevated
thyroid-stimulating hormone (TSH) levels with free
thyroxine concentrations within the reference range, is a
common disorder that increases with age and affects up
to 18% of the elderly, with a higher prevalence in women
compared to men. Prospective data have shown an in-
creased risk of coronary heart disease events, heart failure,
and cardiovascular mortality among affected adults. Con-
flicting results have been found on the association between
subclinical hypothyroidism and cognitive impairment, de-
pression and the risk of fractures. Management strategies
including screening and treatment of subclinical hypo-
thyroidism are still controversial, while the ongoing
European randomised controlled trial “TRUST” targets to
solve these uncertainties. This narrative review aims to as-
sess current evidence on the clinical aspects, as well as
screening and treatment recommendations in adults with
subclinical hypothyroidism.
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Subclinical hypothyroidism
Subclinical hypothyroidism is biochemically defined as el-
evated levels of thyroid-stimulating hormone (TSH) with
normal levels of free thyroxine (fT4) [1], while controver-
sies exist on the limits of the TSH reference range [2].
The prevalence of subclinical hypothyroidism is large and
ranges between 3% and 18% in the adult population, with
women, elderly persons, and iodine sufficient populations
being affected more often [3]. An international survey has
List of abbreviations
CHD coronary heart disease
CI confidence interval
fT4 free thyroxine
GP general practitioner
HR hazard ratio
NYHA New York Heart Association
RCT randomised controlled trial
TSH thyroid-stimulating hormone
demonstrated that 94% of the general practitioners (GPs)
have diagnosed subclinical hypothyroidism in a patient
during the past year [4, 5]. Despite the large prevalence,
evidence on screening and the benefits and risks of treat-
ment is still controversial [2].
The most common cause of subclinical hypothyroidism is
chronic autoimmune thyroiditis associated with antithyroid
peroxidase antibodies (Hashimoto’s thyroiditis) [6]. Indi-
viduals with subclinical hypothyroidism are often asympto-
matic, but clinical manifestations can include non-specific
complaints or symptoms similar to those seen in overt hy-
pothyroidism, such as fatigue, weakness, weight gain, cold
intolerance, and constipation [6].
Adverse clinical effects of overt thyroid disorders are well
known, and given the multiple actions of thyroid hormones
on the heart, the vessels, bones and brain, long-term ad-
verse outcomes could be suspected even in subclinical dys-
function. Table 1 provides an overview of the level of evid-
ence on the association between subclinical hypothyroid-
ism and various clinical conditions.
With the aim to assess current evidence on the clinical as-
pects of subclinical hypothyroidism as well as the risks
and benefits of its screening and treatment, we have per-
formed a narrative review based on already conducted sys-
tematic reviews [7, 8] and other recently published non-
systematic reviews [6, 9], with additional information re-
trieved from systematic reviews on risks of subclinical
hypothyroidism [10, 11]. The evidence has been updated
by a Pubmed search on the risks and treatment of subclin-
ical hypothyroidism of most recent articles published until
2014.
Natural course and progression to
overt hyperthyroidism
Individuals with subclinical hypothyroidism are at risk for
progression to overt thyroid dysfunction with an average
yearly progression rate of 2% to 6% and an increased risk
in females, individuals with higher levels of TSH, and in
the presence of antithyroid peroxidase antibodies, although
those without antithyroid peroxidase antibodies have also a
higher risk of progression [12]. In contrast, TSH levels nor-
malise in 15% to 65% of those with a single elevated TSH
without treatment, over follow-up periods going from 1 to
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6 years, and the likelihood of spontaneous recovery is high-
er with TSH levels <10 mIU/l [13].
TSH levels vary throughout the day and are highest at
night, and considerable variations within the same person
over months can occur that can be accentuated by sleep
deprivation or exercise [14]. Serum TSH is known to in-
crease with age, while this increase might not be associated
with mortality [15] and might even be associated with
longevity as suggested by the Leiden 85+ Study that pro-
spectively followed 599 individuals from age 85 years
through age 89 years [16]. Other reasons for persistent or
transient TSH elevation with normal fT4 levels in the ab-
sence of thyroid pathologies include the recovery phase
after major illness (euthyroid sick syndrome), obesity, ad-
renal insufficiency, TSH-assay problems (i.e., presence of
heterophilic antibodies), medications (i.e., amiodarone,
sertraline, lithium, tyrosine-kinase inhibitors, etc.), chronic
renal failure, central hypothyroidism, or in rare cases muta-
tions leading to the inactivation of the TSH receptor [9].
Based on the population mean and the finding in the Wick-
ham survey that already TSH levels above 2 mIU/l have
an increased risk of developing hypothyroidism in the fu-
ture [12], the upper limit of the TSH reference range is still
under debate [14]. The fact that millions of people would
be identified with subclinical hypothyroidism especially in
the light of raising TSH levels over the lifetime and given
the lack of evidence on adverse outcomes and therapeutic
consequences in individuals with high normal TSH levels
speak against narrowing the TSH reference level [14].
Cardiovascular risk and heart failure
Thyroid hormones are well known to act on the heart and
vasculature, and the impact of subclinical thyroid dysfunc-
tion on the cardiovascular system has been an important
topic of research in recent years. Subclinical hypothyroid-
ism can lead to impaired systolic and diastolic cardiac func-
tion [17] as well as vascular dysfunction with increased
vascular stiffness and endothelial dysfunction [18]. A
pooled analysis of individual participant data has found
an increase in heart failure events in individuals with a
TSH of 10 mIU/l and higher compared to euthyroid con-
trols with a hazard ratio (HR) 1.86 (95% confidence inter-
val [CI] 1.27–2.72) [11] (table 2). Subclinical hypothyroid-
ism has also been associated with an increased risk of fatal
and non-fatal coronary heart disease (CHD) events [10].
An individual participant data analysis including more than
55,000 participants showed an age and sex-adjusted HR
of 1.89 (95% CI 1.28–2.80) for CHD events in persons
with TSH levels above 10 mIU/l [10] compared with eu-
thyroid individuals, and a corresponding HR of 1.58 (95%
CI 1.10–2.27) for CHD mortality (table 2). Risks were not
increased for participants with TSH levels <7 mIU/l, and
there was a significant trend for the risk of CHD events and
mortality at higher TSH levels. Mortality from any cause
was not increased. In line with the results from the indi-
vidual participant data analysis, another study that had been
published later did not show an association between sub-
clinical hypothyroidism and overall death in the oldest old
[15]. In contrast, the Leiden 85+ Study showed a reduced
risk of cardiovascular and overall mortality in subclinically
hypothyroid individuals aged 85years [16]. These findings
might suggest an interaction of age on the effects of thyroid
hormones, which could not be demonstrated in the indi-
vidual participant data analysis that assessed outcomes in
people of all ages [10].
The increased cardiovascular risk that is primarily ob-
served with TSH levels of 10 mIU/l and above can be ex-
plained by several mechanisms. TSH has known effects
on the endocrine system, and studies have shown elevated
total cholesterol and a higher prevalence of dyslipidaemia
in individuals with subclinical hypothyroidism [19]. A sys-
tematic review including 13 heterogeneous studies con-
cluded that thyroxine treatment leads to a reduction in ser-
um total cholesterol and LDL cholesterol in persons with
subclinical hypothyroidism [20]; this finding has been con-
firmed in subsequent randomised controlled trials (RCTs)
[18]. Evidence on the association of subclinical hypo-
thyroidism with increased blood pressure is controversial.
In a cross-sectional study, Liu et al. found an increased
blood pressure in these individuals [21], while this finding
could not be confirmed in other studies [22]. An interven-
tional study including 56 women with subclinical hypo-
thyroidism found an elevated systolic and diastolic blood
pressure, serum cholesterol and homocystein levels com-
pared to healthy controls, with normalisation of these
factors after 18 months of levothyroxine therapy [23]. One
prospective cohort study found a higher prevalence but
Table 1: Level of evidence in 2014 on the risks of treatment and the benefits of subclinical hypothyroidism.
Clinical condition Strength of association Benefits of treatment
TSH 4.5–9.9 mIU/l TSH ≥10 mIU/l
Progression to overt hypothyroidism Good Stronger Effective, especially if
TSH ≥10 mU/l
Elevation in serum total cholesterol and LDL Fair Stronger Insufficient
Risk of coronary heart disease Insufficient Stronger No evidence
Risk of congestive heart failure Insufficient Stronger No evidence
Cardiac dysfunction Insufficient Insufficient Insufficient
Systemic symptoms of hypothyroidism Insufficient Insufficient Insufficient
Neuropsychiatric symptoms (e.g., depression, cognitive dysfunction) Insufficient Insufficient Insufficient
Muscle strength Insufficient Insufficient Insufficient
Fatigue Insufficient Insufficient Insufficient
Risks of treatment
Development of subclinical hyperthyroidism 14%–21%
Adapted according to [59]
LDL = low-density lipoprotein cholesterol; TSH = thyroid-stimulating hormone
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not incidence of metabolic syndrome in adults with sub-
clinical hypothyroidism [24], while another large cohort
study could not find a difference in weight change in these
individuals [25]. Other possible explanations for the in-
creased cardiovascular risk in persons with subclinical hy-
pothyroidism include increased carotid intima-media thick-
ness [19], hypercoagulability, insulin resistance, oxidative
stress [6], and endothelial dysfunction [18]. A reduction in
carotid intima-media thickness [19] and improvement of
brachial artery endothelial function following thyroxine re-
placement in individuals with subclinical hypothyroidism
has been shown [18].
In a small RCT, normalisation of TSH levels by thyroxine
replacement therapy led to an improvement in cardiac
function [17], and recent findings based on retrospective
administrative data suggested that thyroxine treatment
leads to a reduction in ischaemic heart disease in younger
individuals, but not in persons aged 70 years or older [26].
Adequately powered RCTs examining a potential reduction
of cardiovascular events through restoration of euthyroid-
ism are lacking.
Thyroid hormones have known effects on heart rate and
cardiac excitability. In contrast to the increased risk of at-
rial fibrillation in patients with excess thyroid hormones
[27], evidence on this association in individuals with sub-
clinical hypothyroidism is conflicting, while recent obser-
vational data have suggested a protective effect of subclin-
ical hypothyroidism on the development of atrial fibrilla-
tion [28].
Musculoskeletal system and functional
capacity
Persons with subclinical hypothyroidism more often suffer
from weakness and myalgia [29], and reduced muscle
strength has been shown in these individuals [30]. Con-
firming this hypothesis, beneficial effects of levothyroxine
replacement on strength measurements [30] and cardiop-
ulmonary exercise performance [31] have been demon-
strated. A possible mechanism for the lower exercise capa-
city could be higher oxygen requirements during exercise
in people with subclinical hypothyroidism [31] as well as a
possible association with anaemia [32]. On the other hand,
large cohort studies did not find a reduction in function-
al mobility or functional capacity assessed in elderly indi-
viduals with subclinical hypothyroidism [33, 34], and per-
sons with only mild elevations of TSH even revealed a
slightly better mobility than euthyroid controls [33].
High TSH levels as seen in hypothyroidism have been
shown to directly affect bone metabolism through inhib-
ition of osteoclast formation and survival, osteoblast dif-
ferentiation and expression of collagen type 1 [35]. For
subclinical hypothyroidism, an increased risk for hip frac-
tures in men (multivariable-adjusted HR 2.31 [95% CI
1.25–4.27]) but not in women was demonstrated in a pro-
spective cohort study including 3,567 participants with a
median follow-up of 13 years [36]. In contrast, another pro-
spective study of 25,205 individuals from Norway did not
show a significant association with hip or forearm fractures
when the results were adjusted for age, BMI and smoking
status except in a subgroup of women with TSH >4.0 mIU/l
and negative antithyroid peroxidase antibodies, where the
HR for hip fracture was 1.75 (95% CI 1.24–2.46) [37].
Neuropsychiatric symptoms
An association between subclinical hypothyroidism and
mood disorders including depression and increased anxiety
[38], as well as a reduced quality of life [18] have been sug-
gested, whereas other studies did not confirm these find-
ings [39]. Treatment failure for depression has been more
commonly observed in patients with subclinical hypo-
thyroidism [40]. Evidence of the association between cog-
nitive dysfunction and subclinical hypothyroidism is con-
flicting [16, 41], and the most recent population-based
cross-sectional study examining 2,050 participants includ-
ing 141 individuals with subclinical hypothyroidism did
not show an association with mild cognitive impairment,
which represents the earliest detectable clinical stage of
cognitive impairment [42]. In the currently largest RCT
evaluating the impact of thyroxine replacement on cognit-
ive function with inclusion of 94 elderly participants with
subclinical hypothyroidism, treatment did not lead to an
improvement of cognitive function after a follow-up of 12
months [43].
Other clinical implications
The influence of overt hypothyroidism on gastrointestinal
mobility with symptoms such as constipation are well
known. A recent study demonstrated impaired gastric
motility and consecutive symptoms in premenopausal wo-
men with subclinical hypothyroidism [44]. Given the sug-
gested associations between subclinical hypothyroidism
and the metabolic syndrome, Chung et al. performed a
cross-sectional study and found a dose-dependent relation
between TSH levels and non-alcoholic fatty liver diseases
in individuals with subclinical and overt hypothyroidism
[45].
Table 2: Risk for Coronary Heart Disease (CHD) mortality and events and heart failure events according to thyroid-stimulating hormone levels.
TSH level HRs for CHD mortality (95% CI) HRs for CHD events (95% CI) HRs for heart failure events (95% CI)
TSH 10.0–19.9 mIU/l 1.58 (1.10–2.27) 1.89 (1.28–2.80) 1.86 (1.27–2.72)
TSH 7.0–9.9 mIU/l 1.42 (1.03–1.95) 1.17 (0.96–1.43) 1.65 (0.84–3.23)
TSH 4.5‒6.9 mIU/l 1.09 (0.91–1.30) 1.00 (0.86–1.18) 1.01 (0.81–1.26)
TSH 0.45–4.49 mIU/l* 1.00 (reference) 1.00 (reference) 1.00 (reference)
TSH 0.10–0.44 mIU/l 1.24 (0.96–1.61) 1.27 (1.03–1.58) 1.31 (0.88–1.95)
TSH <0.10 mIU/l 1.84 (1.12–3.00) 1.08 (0.69–1.69) 1.94 (1.01–3.72)
Adapted according to [10, 11, 27]. CHD = coronary heart disease; CI = confidence interval; HR = hazard ratio (age and gender-adjusted); TSH = thyroid-stimulating
hormone.
* TSH 0.5–4.49 mIU/l for association between subclinical hypothyroidism and CHD mortality and CHD events.
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To date, there is no strong evidence on the association
between subclinical hypothyroidism and anaemia: persons
with subclinical hypothyroidism had higher mean haemo-
globin levels compared to their euthyroid counterparts in
one cohort study, but this finding was not significant [46].
However, two RCTs have concluded that the addition of
levothyroxine in subclinically hypothyroid patients with
iron-deficiency anaemia lead to a more pronounced in-
crease in haemoglobin and ferritin than treatment with iron
salt alone [32, 47], whereas the restoration of euthyroidism
has not led to a change in haemoglobin in another RCT in-
cluding 66 women with subclinical hypothyroidism [48].
Subclinical hypothyroidism and
pregnancy
For pregnant women, lower trimester-specific TSH refer-
ence ranges should be used due to the changes in thyroid
physiology during pregnancy. Thyroid hormones are cru-
cial for the normal foetal maturation and brain develop-
ment, and the foetus relies on placental passage of maternal
thyroid hormones during the first trimester of pregnancy
due to the immaturity of the foetal thyroid gland and the
consecutive inability to produce sufficient thyroid hor-
mones. Foetal consequences of maternal overt hypo-
thyroidism including perinatal morbidity and mortality and
neurological impairment are widely known, and subclinical
hypothyroidism has also been associated with adverse out-
comes during pregnancy. Subclinical hypothyroidism af-
fects 0.5% to 2.5% of women during reproductive age and
can lead to higher rates of placental abruption [49], preg-
nancy loss [50], gestational hypertension, and severe pree-
clampsia [51]. An increased risk of preterm delivery [49]
has been found in subclinically hypothyroid women and
might explain some of the neonatal complications seen in
neonates born to those mothers, including neonatal respir-
atory distress and an increased risk of neonatal death, with
however conflicting data among different studies [49, 50].
Whether maternal subclinical hypothyroidism leads to im-
paired cognitive development in children is uncertain [52].
Recommendations for screening and
treatment
Due to the lack of large-scale RCTs examining relevant
clinical outcomes, current screening and treatment recom-
mendations are principally based on observational data,
small clinical trials with short follow-up durations and ex-
pert opinions. Screening recommendations vary widely
across different medical societies and expert groups (table
3) [6]. Overall, screening of the general population cannot
be recommended and should likely be restricted to high
risk individuals including patients with autoimmune dis-
orders, a personal or family history of thyroid disease, or
those with potential symptoms (table 3). Also in asymp-
tomatic pregnant women evidence for universal screening
is equivocal, and most professional societies recommend
a targeted screening strategy, e.g., in women coming from
iodine insufficient areas or in those with morbid obesity,
diabetes type 1, a family or personal history of thyroid dis-
ease or a history of abortion or preterm delivery [53]. Be-
cause of the lack of large RCTs addressing thyroid screen-
ing, the exact group that would benefit from screening
remains unclear.
The central question in medical care of patients with sub-
clinical hypothyroidism is whether these patients should
be treated or not. Several interventional placebo-controlled
trials have examined the effect of levothyroxine replace-
ment in individuals with subclinical hypothyroidism with
assessment of various outcomes, such as surrogate markers
of cardiovascular risk (carotid intima-media thickness, ser-
um lipid levels, body mass index) [19], cardiac function
[17], mood disorders, symptoms [54], and cognition [43],
with major limitations including small sample sizes (up
to 110 participants) and short follow-up durations. A Co-
chrane Systematic Review published in 2007 concluded
that evidence suggests a beneficial effect of thyroid hor-
mone replacement on surrogate markers for cardiovascular
risk, such as improved serum cholesterol levels and cardiac
function, but the impact on clinical outcomes could not be
assessed given the current data. Therefore, the authors con-
cluded that no clear recommendation concerning efficacy
and safety of thyroid hormone replacement in individuals
with subclinical hypothyroidism could be stated and that
the decision whether or not to treat should be individualised
[7]. Table 1 summarises the evidence on treatment benefits
in various clinical conditions.
Most experts and societies suggest treatment of subclinical
hypothyroidism if TSH levels are >10 mIU/l based on the
available evidence [2], even though long-time risks and
benefits of treatment in this population are not known.
For persons with moderately elevated TSH concentrations
between 4.5–10 mIU/l, TSH levels should be monitored
every 6 to 12 months [2] and treatment outside of a clinical
Table 3: Recommendations for screening of subclinical hypothyroidism in asymptomatic adults.
Organisation Screening recommendation
American Thyroid Association, American Association of Clinical
Endocrinologists and The Endocrine Society
Routine examination in all adults, including pregnant women or women wishing to become pregnant,
especially if symptoms/signs compatible with thyroid dysfunction
College of American Pathologists Women ≥50 years consulting a physician, all geriatric patients admitted to a hospital and at least
every five years
American Academy of Family Physicians Patients ≥60 years
American College of Obstetrics and Gynecology High risk patients (autoimmune disorder, family history for thyroid disease)
American College of Physicians Women >50 years with recent occurrence of symptoms compatible with thyroid disorder
Royal College of Physicians No screening indicated
U.S. Preventive Services Task Force Insufficient evidence for or against screening
Swiss Society of Endocrinology and Diabetes [55] Women, age ≥40 years, unspecific complaints, geriatric patients, patients at high risk: after therapy of
overt hyperthyroidism, combined autoimmune syndrome, smokers
Adapted according to [59]
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trial is currently not recommended [1]. Current guidelines
from the Swiss Society of Endocrinology and Diabetes
recommend treatment of individuals with subclinical hy-
pothyroidism according to a risk stratification taking into
account a TSH level >10 mIU/l, the presence of goitre,
antithyroid antibodies, cardiovascular risk factors or pre-
valent CHD, smoking, dyslipidaemia, clinical symptoms,
ovulatory dysfunction or infertility, and pregnancy [55]. In
pregnant women with TSH levels above the trimester-spe-
cific TSH cutoffs and in women with infertility or wish-
ing to become pregnant with TSH values of 2.5 mIU/l or
higher, initiation of thyroxine replacement therapy is re-
commended [2, 53]. All these recommendations are based
on expert opinion in the absence of randomised clinical tri-
als on the treatment effects of subclinical hypothyroidism
on clinical outcomes. The Swiss guidelines recommend an
initial treatment dose of 25 ug daily in persons aged above
50 years or with known CHD; in all other individuals, le-
vothyroxine should be dosed at 50 to 75 µg daily at the
beginning of treatment with the goal of reducing the TSH
level into the reference range [55]. The European Thyroid
Association recommends similar thyroxine starting doses,
with 25–50 ug daily in elderly individuals or those with
cardiac disease, and weight-adjusted starting doses of ap-
proximately 1.5 µg/kg daily in all other persons [56]. Be-
fore treatment is initiated, a follow-up blood test should
be ordered after three to six months of the initial diagnos-
is given the high rate of spontaneous normalisation of el-
evated TSH levels (see differential diagnoses of TSH el-
evations above in chapter “Natural course and progression
to overt hyperthyroidism”). Risks of treatment have been
mainly associated with overtreatment, which is reported in
14% to 21% of subclinically hypothyroid individuals on
thyroxine replacement therapy [3]. Possible adverse effects
from thyroxine include atrial fibrillation, angina pectoris,
congestive heart failure, and symptoms associated with ex-
cess thyroid hormone such as nervousness and palpitations
[1]. Overtreatment can result in a decrease of bone mineral
density and an increase in fracture risk [57].
Despite this lack of evidence, levothyroxine is a widely
prescribed drug, and prescription rates are rising. Man-
agement strategies regarding the initiation and dosing of
thyroxine substitution differ significantly between different
countries with treatment initiation rates varying from 35%
in The Netherlands to 75% in Germany [4]. 54% of the
Swiss GPs reported to start a thyroxine replacement ther-
apy in patients with subclinical hypothyroidism [4]. These
variations in treatment strategies and the existing contro-
versy in guidelines concerning screening and treatment in
individuals with subclinical hypothyroidism reflect the cur-
rent uncertainty. Several experts have called for a large
RCT to end this uncertainty and controversy about man-
agement strategies of these persons [1, 2, 7].
Conclusion and perspectives: the
TRUST trial
With the aim to resolve these uncertainties regarding the
risks and benefits of treatment on relevant clinical out-
comes in elderly persons with subclinical hypothyroidism,
the first adequately powered RCT has been initiated [58].
The TRUST Study (Thyroid hormone Replacement for Un-
treated older adults with Subclinical hypothyroidism: a ran-
domised placebo-controlled Trial) is a European multi-
centre study that is conducted in five centres in four
European countries including Switzerland, Scotland, Ire-
land and The Netherlands, and examines thyroid hormone
replacement therapy versus placebo in elderly individuals
with persisting subclinical hypothyroidism
(www.trustthyroidtrial.com). A total of 3,000 participants
will be enrolled in all sites. Participating centres in Switzer-
land include the Inselspital Bern and the University Hos-
pital of Lausanne that are both supported by the local in-
stitutes of family medicine, BIHAM (Berner Institut für
Hausarztmedizin) and IUMG (Institut universitaire de mé-
decine générale) in Lausanne, with a large number of parti-
cipants recruited in general practices (fig. 1). A broad pop-
ulation of community-dwelling individuals aged 65 years
or older with persistent subclinical hypothyroidism,
defined as a TSH level 4.6 to 19.9 mIU/l measured on two
or more occasions at least three months apart with normal
fT4 levels, are included in the study to ensure a good gener-
alisability of the study results and allow direct conclusions
for clinical decisions that need to be taken by GPs. To meet
this aim, only few exclusion criteria have been defined:
these include patients on thyroid-altering medication, re-
Figure 1
TRUST trial. Process for inclusion in the TRUST trial: Confirmation
of subclinical hypothyroidism and patient visits during the course of
the trial. See chapter “Conclusion and perspectives: The TRUST
trial” for more details. Figure: adapted according to [59].
fT4 = free thyroxine; GP = general practitioner; TSH = thyroid-
stimulating hormone
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cent thyroid surgery or radio-iodine therapy within the last
year, grade IV NYHA heart failure, recent hospitalisation
for major illness to exclude patients with euthyroid sick
syndrome, a prior clinical diagnosis of dementia, and acute
coronary syndrome within the last four weeks. The parti-
cipants are randomised to either placebo or levothyroxine
with a starting dose of 50 µg daily (25 µg in patients with
a weight <50 kg or a history of CHD) and with subsequent
dose adjustments according to the serum TSH level. Parti-
cipants are followed for one to four years to reach the target
number of cardiovascular outcomes, and a number of rel-
evant multimodal clinical outcomes are assessed: primary
outcomes include fatal and non-fatal cardiovascular events,
and disease-specific quality of life, secondary outcomes are
muscle strength, blood pressure, cognitive function, func-
tional capacity, general quality of life, and mortality.
Due to the current lack of evidence regarding the optimal
treatment strategy in individuals with subclinical hypo-
thyroidism, to date the best management of such persons is
the inclusion in ongoing trials. For persons who cannot be
included in the trial, we do not recommend initiating treat-
ment in individuals with TSH levels <10 mIU/l, but to fol-
low serum TSH values [2]. If TSH levels exceed 10 mIU/l,
levothyroxine substitution might be considered, but even in
these persons, there is no direct evidence from RCTs justi-
fying treatment [8].
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Figures (large format)
Figure 1
TRUST trial.
Process for inclusion in the TRUST trial: Confirmation of subclinical hypothyroidism and patient visits during the course of the trial. See chapter
“Conclusion and perspectives: The TRUST trial” for more details. Figure: adapted according to [59].
fT4 = free thyroxine; GP = general practitioner; TSH = thyroid-stimulating hormone
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